PDS Biotechnology (PDSB) Misses Q1 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to PDS Biotechnology (PDSB) Misses Q1 EPS by 24c

PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update

May 13, 2020 6:00 AM EDT

FLORHAM PARK, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune® T-cell activating technology, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.

First Quarter 2020 and Recent Business Highlights

Initiated novel vaccine development programs for COVID-19 and universal influenza;Announced pre-clinical collaboration with Farmacore... More